← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Novelmed Therapeutics, Inc.
Twinsburg, OH
$19,788,255
Total funding
22
Grants
Funding over time
peak $3.1M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$19,788,255 · 22
By mechanism
R44$17,703,337 · 13
R43$1,876,770 · 8
R41$208,148 · 1
Investigators at Novelmed Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Preclinical and Clinical Evaluation of Humanized NM9405$1,277,607
R44 · FY2017 · HL
Preclinical and Clinical Evaluation of Humanized NM9405$1,159,286
R44 · FY2015 · HL
Disease Modifying Biologics for Rheumatoid Arthritis$968,470
R44 · FY2012 · AG
Novel Anti-Inflammatories for Cardiopulmonary Bypass$963,269
R44 · FY2008 · HL
Disease Modifying Biologics for Rheumatoid Arthritis$929,079
R44 · FY2011 · AG
Alternative Pathway Inhibitors for Orphan Indication$889,438
R44 · FY2014 · HL
Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis$849,661
R44 · FY2014 · DK
Disease Modifying Biologics for Rheumatoid Arthritis$791,681
R44 · FY2010 · AG
Controlling Inflammation Due to Cardiac Devices$719,654
R44 · FY2011 · HL
Inhibition of Cardiac Device Induced Cellular Dysfunction in Pigs$691,377
R44 · FY2012 · HL
Controlling Inflammation Due to Cardiac Devices$633,313
R44 · FY2012 · HL
Novel Treatments to Abolish Inflammatory Mediators in Hemodialysis$601,912
R44 · FY2015 · DK
Complement Inhibitors for Macular Degeneration$597,897
R44 · FY2013 · EY
Single Therapy for Wet AMD & Geographic Atrophy$548,724
R44 · FY2014 · EY
Alternative Pathway Inhibitors for Orphan Indication$542,572
R44 · FY2013 · HL
Disease Modifying Treatment for Hemolytic Disorders$533,165
R44 · FY2021 · HL
Novel Anti-Inflammatories for Cardiopulmonary Bypass$522,061
R44 · FY2009 · HL
Inhibition of Cardiac Device Induced Cellular Dysfunction in Pigs$516,118
R44 · FY2010 · HL
Inhibition of Cardiac Device Induced Cellular Dysfunction in Pigs$503,352
R44 · FY2011 · HL
Preclinical and Clinical Evaluation of Humanized NM9405$467,832
R44 · FY2014 · HL